Previous Myocardial Injury Tied to Worse COVID-19 Outcomes
Significant but weaker associations with selected adverse outcomes seen for preexisting hypertension, diabetes, and ischemic heart disease
Significant but weaker associations with selected adverse outcomes seen for preexisting hypertension, diabetes, and ischemic heart disease
Furoscix is a wearable, pre-programmed on-body furosemide delivery system for outpatient self-administration.
Investigators urge health care professionals who manage patients with ED to discuss the risk of future cardiovascular disease.
The placebo-controlled, event-driven DELIVER study included 6263 patients.
Promising therapies still need to be further evaluated in clinical trials.
For those aged 40 to 59 years, the decision to initiate low-dose aspirin for primary prevention of CVD should be individualized
Among men with ischemic heart disease, coprescription of nitrates and PDE5 inhibitors not linked to increased risk for cardiovascular events
Apixaban is a direct oral anticoagulant that relies less on kidney excretion.
Association stronger in most recent decades and among those with schizophrenia
Although cardiovascular mortality rates declined, clinicians should still be vigilant to prevent poor outcomes in patients receiving dialysis, according to investigators.